Application of ring-closing metathesis macrocyclization to the development of Tsg101-binding antagonists.

Bioorg Med Chem Lett

Laboratory of Medicinal Chemistry, Center for Cancer Research, National Cancer Institute-Frederick, National Institutes of Health Frederick, MD 21702, United States.

Published: January 2010

HIV-1 viral budding involves binding of the viral Gag(p6) protein to the ubiquitin E2 variant domain of the human tumor susceptibility gene 101 protein (Tsg101). Recognition of p6 by Tsg101 is mediated in part by a proline-rich motif that contains the sequence 'Pro-Thr-Ala-Pro' ('PTAP'). Using the p6-derived 9-mer sequence 'PEPTAPPEE', we had previously improved peptide binding affinity by employing N-alkylglycine ('peptoid') residues. The current study applies ring-closing metathesis macrocyclization strategies to Tsg101-binding peptide-peptoid hybrids as an approach to stabilize binding conformations and to observe the effects of such macrocyclization on Tsg101-binding affinity and bioavailability.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2818493PMC
http://dx.doi.org/10.1016/j.bmcl.2009.10.105DOI Listing

Publication Analysis

Top Keywords

ring-closing metathesis
8
metathesis macrocyclization
8
application ring-closing
4
macrocyclization development
4
development tsg101-binding
4
tsg101-binding antagonists
4
antagonists hiv-1
4
hiv-1 viral
4
viral budding
4
budding involves
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!